Dermalab - Company finances
|
EUR
|
2024
From: 2024-01-26
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 291,788 | 321,799 |
| Profit before tax | 165,277 | -25,487 |
| Net profit | 157,013 | -25,487 |
| Equity | 162,013 | 136,526 |
| Liabilities | 48,720 | 19,052 |
| Non-current assets | 47,434 | 49,288 |
| Current assets | 163,299 | 106,290 |
| Total assets | 210,733 | 155,578 |
|
Taxes paid
|
||
| STI taxes | 33,272 | 40,411 |
| Social insurance contributions | 5,469 | 18,644 |
|
Financial indicators
|
||
| Revenue change y/y | - | +10.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 74.5% | -16.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 96.9% | -18.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 53.8% | -7.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 56.6% | -7.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 76,420 | 48,881 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Dermalab - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-03-27 | 2026-03-27 | 958.89 |
| 2026-03-17 | 2026-03-19 | 958.89 |
| 2026-02-18 | 2026-02-19 | 1103.72 |
| 2026-01-21 | 2026-02-08 | 0.61 |
| 2026-01-16 | 2026-01-18 | 1025.53 |
| 2025-11-18 | 2025-11-26 | 4.88 |
| 2025-07-28 | 2025-08-07 | 5.51 |
| 2025-07-26 | 2025-07-27 | 301.68 |
| 2025-07-25 | 2025-07-25 | 307.19 |
| 2025-07-24 | 2025-07-24 | 1724.10 |
| 2025-07-16 | 2025-07-23 | 1718.59 |
| 2025-05-16 | 2025-05-22 | 2041.68 |
| 2025-04-30 | 2025-04-30 | 60.00 |
| 2025-04-24 | 2025-04-27 | 63.96 |
| 2025-04-17 | 2025-04-23 | 60.00 |
| 2025-04-16 | 2025-04-16 | 1662.86 |
| 2025-03-18 | 2025-03-26 | 1465.92 |
Dermalab - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Dermalab is: 2 €
| From | To | Overdue, € |
|---|---|---|
| 2026-08-31 | 2026-09-02 | 2.21 |
| 2026-07-03 | 2026-07-07 | 25.68 |
| 2026-06-30 | 2026-07-02 | 23.4 |
| 2026-06-28 | 2026-06-29 | 10910.84 |
| 2026-06-04 | 2026-06-27 | 3.0 |
| 2026-05-28 | 2026-06-01 | 3.0 |
| 2026-05-08 | 2026-05-20 | 3.94 |
| 2026-04-30 | 2026-05-07 | 3.0 |
| 2026-04-17 | 2026-04-20 | 3.0 |
| 2026-04-09 | 2026-04-16 | 3.34 |
| 2026-04-01 | 2026-04-08 | 3.0 |
| 2026-03-20 | 2026-03-21 | 2893.84 |
| 2026-03-08 | 2026-03-17 | 0.84 |
| 2026-02-28 | 2026-03-07 | 0.28 |
| 2026-02-03 | 2026-02-16 | 0.14 |
| 2026-01-31 | 2026-02-02 | 0.02 |
| 2025-12-03 | 2025-12-05 | 6.92 |
| 2025-11-28 | 2025-12-02 | 1.23 |
| 2025-11-12 | 2025-11-22 | 1.23 |
| 2025-11-09 | 2025-11-11 | 6.09 |
| 2025-11-08 | 2025-11-08 | 122.1 |
| 2025-10-30 | 2025-11-07 | 1.23 |
| 2025-10-02 | 2025-10-23 | 1.23 |
| 2025-09-02 | 2025-09-03 | 7.15 |
| 2025-09-01 | 2025-09-01 | 4739.73 |
| 2025-08-31 | 2025-08-31 | 4732.35 |
| 2025-08-28 | 2025-08-30 | 4732.58 |
| 2025-08-09 | 2025-08-27 | 11.58 |
| 2025-08-01 | 2025-08-08 | 4.86 |
| 2025-07-28 | 2025-07-31 | 2999.0 |
| 2025-07-11 | 2025-07-20 | 3.54 |
| 2025-07-02 | 2025-07-10 | 2.95 |
| 2025-07-01 | 2025-07-01 | 2205.51 |
| 2025-06-28 | 2025-06-30 | 2201.69 |
| 2025-06-27 | 2025-06-27 | 5437.15 |
| 2025-06-24 | 2025-06-26 | 5674.02 |
| 2025-06-19 | 2025-06-23 | 7162.61 |
| 2025-01-01 | 2025-01-01 | 17.36 |
| 2024-12-30 | 2024-12-31 | 12.24 |
| 2024-12-03 | 2024-12-24 | 12.24 |
| 2024-12-01 | 2024-12-02 | 9479.44 |
| 2024-11-28 | 2024-11-30 | 9479.68 |
| 2024-10-01 | 2024-10-09 | 1794.88 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Dermalab, UAB (code 306669378) is a Private Limited Liability Company engaged in the manufacture of other inorganic basic chemicals. In the latest financial year, 2025, the company generated revenue of EUR 321.8K, up 10.3% year on year from EUR 291.8K in 2024. However, profitability weakened materially: net profit moved from EUR 157.0K in 2024 to a net loss of EUR 25.5K in 2025, and the profit margin fell from 53.8% to -7.9%. The two-year trend therefore shows revenue growth alongside a sharp deterioration in earnings. At the balance sheet level, total assets declined from EUR 210.7K in 2024 to EUR 155.6K in 2025, while equity decreased from EUR 162.0K to EUR 136.5K and liabilities fell from EUR 48.7K to EUR 19.1K. The company retained a strong equity ratio of 87.8% and a low debt-to-equity ratio of 0.14. Asset turnover stood at 2.07x. Revenue per employee was EUR 53.6K, while profit per employee was negative at EUR 4.2K in 2025.